Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1719556 | 0.92 | PPARG (0.71) | PPARGPPARA | |
| SCHEMBL1720330 | 0.88 | PPARG (0.70) | PPARGPPARA | |
| SCHEMBL1720151 | 0.88 | PPARG (0.61) | PPARG | |
| SCHEMBL1720777 | 0.87 | PPARG (0.69) | PPARGPPARA | |
| SCHEMBL5065105 | 0.85 | PPARG (0.61) | PPARGPPARA | |
| SCHEMBL1721007 | 0.85 | PPARG (0.61) | PPARGPPARA | |
| SCHEMBL2786404 | 0.84 | PPARG (0.74) | PPARGPPARA | |
| SCHEMBL1719748 | 0.82 | PPARG (0.56) | PPARGPPARA | |
| SCHEMBL14274949 | 0.81 | PPARG (0.64) | PPARGPPARA | |
| SCHEMBL1719558 | 0.80 | PPARG (0.70) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569904-B1 | SUBSTITUTED ARYLALCANOIC ACID DERIVATIVES AS PPAR PAN AGONISTS WITH POTENT ANTIHYPERGLYCEMIC AND ANTIHYPERLIPIDEMIC ACTIVITY | SHENZHEN CHIPSCREEN BIOSCIENCES LTD (CN) | 2012-01-11 | — | — | EP | disclosed |
| US-20080051321-A1 | Substituted arylalcanoic acid derivatives as ppar pan agonists with potent antihyperglycemic and antihyperlipidemic activity | LU XIAN-PING | 2008-02-28 | — | — | US | disclosed |
| US-7268157-B2 | Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity | SHENZHEN CHIPSCREEN BIOSCIENCES, LTD. (CN) | 2007-09-11 | — | — | US | disclosed |
| US-20040142921-A1 | Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (CN) | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142921-A1 | Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity | GPR119, PPARG, PPARA | PPARG 2/4885PPARA 3/4885 |
| US-20080051321-A1 | Substituted arylalcanoic acid derivatives as ppar pan agonists with potent antihyperglycemic and antihyperlipidemic activity | GPR119, PPARG, PPARA | PPARG 2/4885PPARA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.